Base Year
Historical Year
Forecast Year
The lupus nephritis treatment market size was valued at USD 1.8 billion in 2023, driven by the emphasis on preventing kidney failures. The market is expected to grow at a CAGR of 7.5% during the forecast period of 2024-2032, with the values likely to rise from USD 1.9 billion in 2024 to USD 3.4 billion by 2032.
Lupus is an autoimmune disease wherein the immune system starts attacking the healthy cells of the body. Lupus nephritis is the specific targeting and damage to the kidneys. Proliferative nephritis is the most severe kind of nephritis that may even cause permanent damage to the kidneys. Lupus nephritis treatment includes the administration of corticosteroids, immunosuppressants, blood pressure medications and diuretics. Dietary changes like reduced sodium intake and lesser consumption of protein are also advised as a part of the treatment.
Lupus nephritis treatment has observed significant evolution in recent years. B cells play a pivotal role in the pathogenesis of lupus nephritis. Hence, major areas of action in any medication revolve around either B-cell depletion or anti-B-cell activation. Currently, Rituximab is a commonly used medication for lupus nephritis treatment. Numerous medications are also under clinical trials, which are further expected to fuel the lupus nephritis treatment market growth.
Lupus nephritis may lead to chronic kidney failure diseases and is also associated with high blood pressure. Voclosporin (Lupkynis™) has been found safe and effective in treating the disease. It is a structurally modified calcineurin inhibitor, which acts as an immunosuppressant as well as promotes podocyte stability in the kidney. It also led to continuous improvement in proteinuria (presence of protein urine), which is another major symptom of lupus nephritis.
In June 2023, Kyverna Therapeutics, a United States based cell therapy company, received the FDA approval for KYV-101, designed to treat refractory lupus nephritis. The medication works on a novel anti-CD19 chimeric antigen receptor T-cell (CAR T) therapy which depletes B cells, including autoreactive B cells, present in patients with this autoimmune disease. With the advent of new therapies and latest advancements, the lupus nephritis treatment market demand is expected to rise more in the upcoming years.
Market Breakup by Drug Class
Market Breakup by Treatment Type
Market Breakup by Route of Administration
Market Breakup by Distribution Channel
Market Breakup by End User
Market Breakup by Region
The growing convergence of technology into the medical ecosystem has paved the way for artificial intelligence and machine learning enabled diagnosis. The United States, having a robust medical and technical infrastructure, is anticipated to pioneer the lupus nephritis treatment market share in the forecast period. The researchers from University of Houston have also received a USD 3 million grant to offer rapid and precise diagnosis of the disease.
Europe is another major market for lupus nephritis treatment. With a prominent healthcare scenario for the geriatric population, it is home to several leading research and academic institutions working on offering effective treatment options to a wide set of audiences present in the region.
The Asia Pacific region is expected to witness a rapid surge in the lupus nephritis treatment market value, attributed to high investment in building medical infrastructure. There is also an influx of foreign capital, especially from leading medical companies. Government initiatives to spread relevant awareness are also on the rise. Lupus Awareness Month organized every October in Australia is a prime example. This program is aimed at delivering awareness of disease to offer early diagnosis and improve treatment.
The key features of the market report include patent analysis, grants analysis, clinical trials analysis, funding and investment analysis, partnerships, and collaborations analysis by the leading key players. The major companies in the market are as follows:
Kindly note that this only represents a partial list of companies, and the complete list has been provided in the report.
| REPORT FEATURES | DETAILS |
| Base Year | 2023 |
| Historical Period | 2017-2023 |
| Forecast Period | 2024-2032 |
| Scope of the Report |
Historical and Forecast Trends, Industry Drivers and Constraints, Historical and Forecast Market Analysis by Segment:
|
| Breakup by Drug Class |
|
| Breakup by Treatment Type |
|
| Breakup by Route of Administration |
|
| Breakup by End User |
|
| Breakup by Distribution Channels |
|
| Breakup by Region |
|
| Market Dynamics |
|
| Competitive Landscape |
|
| Companies Covered |
|
*While we strive to always give you current and accurate information, the numbers depicted on the website are indicative and may differ from the actual numbers in the main report. At Expert Market Research, we aim to bring you the latest insights and trends in the market. Using our analyses and forecasts, stakeholders can understand the market dynamics, navigate challenges, and capitalize on opportunities to make data-driven strategic decisions.*
Get in touch with us for a customized solution tailored to your unique requirements and save upto 35%!
The market attained a value of about USD 1.8 billion in 2023, driven by the focus on preventing kidney failures associated with lupus nephritis.
The market is anticipated to grow at a CAGR of 7.5% during the forecast period of 2024-2032, likely to reach a market value of USD 3.4 billion by 2032.
The market demand has observed an upswing with the growing incidence of the condition. Moreover, there is also increased focus on early diagnosis and treatment with the help of government initiatives.
Major market trends revolve around the emergence of new medications and therapies like Voclosporin (Lupkynis™) and KYV-101 to treat the disease. Artificial intelligence and machine learning enabled diagnostic methods are also one of the latest trends.
The major regions of the market include the United States, Japan, EU-4 and the United Kingdom. EU-4 is categorised into Germany, France, Italy, and Spain.
The market is divided into NSAIDs, corticosteroids, and immunosuppressants, among others.
Treatment types include medication, dialysis, and kidney transplants.
Major distribution channels include hospital pharmacies, retail pharmacies, and online pharmacies, among others.
Major end users include hospitals, clinics, research and academic labs, among others.
The route of administration can be oral and parenteral, among others.
Key players involved in the market are F. Hoffmann-La Roche Ltd, AstraZeneca, Aurinia Pharmaceuticals Inc., GlaxoSmithKline plc., Bristol-Myers Squibb Company, Eli Lilly and Company, Merck & Co., Inc., Novartis AG, Pfizer Inc., Bayer AG, Sanofi, Sumitomo Corporation, LEO Pharma A/S, Cipla Inc., and Vertice Pharma.
Purchase Full Report
Datasheet
Single User License
One User
Five User License
Five Users
Corporate License
Unlimited Users
How To Order
Our step-by-step guide will help you select, purchase, and access your reports swiftly, ensuring you get the information that drives your decisions, right when you need it.
Select License Type
Choose the right license for your needs and access rights.
Click on ‘Buy Now’
Add the report to your cart with one click and proceed to register.
Select Mode of Payment
Choose a payment option for a secure checkout. You will be redirected accordingly.
Gain insights to stay ahead and seize opportunities.
Get insights & trends for a competitive edge.
Track prices with detailed trend reports.
Analyse trade data for supply chain insights.
Leverage cost reports for smart savings
Enhance supply chain with partnerships.
Connect For More Information
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
Our expert team of analysts will offer full support and resolve any queries regarding the report, before and after the purchase.
We employ meticulous research methods, blending advanced analytics and expert insights to deliver accurate, actionable industry intelligence, staying ahead of competitors.
Our skilled analysts offer unparalleled competitive advantage with detailed insights on current and emerging markets, ensuring your strategic edge.
We offer an in-depth yet simplified presentation of industry insights and analysis to meet your specific requirements effectively.
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City,1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
United States (Head Office)
30 North Gould Street, Sheridan, WY 82801
+1-415-325-5166
Australia
63 Fiona Drive, Tamworth, NSW
+61-448-061-727
India
C130 Sector 2 Noida, Uttar Pradesh 201301
+91-858-608-1494
Philippines
40th Floor, PBCom Tower, 6795 Ayala Avenue Cor V.A Rufino St. Makati City, 1226.
+63-287-899-028, +63-967-048-3306
United Kingdom
6 Gardner Place, Becketts Close, Feltham TW14 0BX, Greater London
+44-753-713-2163
Vietnam
193/26/4 St.no.6, Ward Binh Hung Hoa, Binh Tan District, Ho Chi Minh City
+84-865-399-124
Share